BioLASCO Taiwan Co., Ltd. (TPEX:6662)
28.60
+0.05 (0.18%)
May 29, 2026, 1:30 PM CST
BioLASCO Taiwan Revenue
BioLASCO Taiwan had revenue of 61.01M TWD in the quarter ending March 31, 2026, with 1.91% growth. This brings the company's revenue in the last twelve months to 263.81M, down -13.41% year-over-year. In the year 2025, BioLASCO Taiwan had annual revenue of 262.66M, down -10.20%.
Revenue (ttm)
263.81M
Revenue Growth
-13.41%
P/S Ratio
2.78
Revenue / Employee
2.90M
Employees
91
Market Cap
732.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.66M | -29.83M | -10.20% |
| Dec 31, 2024 | 292.50M | 27.78M | 10.49% |
| Dec 31, 2023 | 264.72M | 28.81M | 12.21% |
| Dec 31, 2022 | 235.91M | 8.33M | 3.66% |
| Dec 31, 2021 | 227.58M | -71.30M | -23.86% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Taiwan Advance Bio-Pharmaceutical | 364.79M |
| TCI GENE | 273.61M |
| Lukas Biomedical | 179.49M |
| NatureWise Biotech & Medicals | 176.77M |
| Vectorite Biomedical | 61.41M |
| Neith | 32.03M |
| SynCore Biotechnology Co.,Ltd | 27.78M |